Global Bladder Cancer Therapeutics Market Is Estimated To Witness Growth Due To Growing Prevalence Of Tumors And Increasing Innovations Of Drugs For Its Treatment

 

Bladder Cancer Therapeutics Market 

Overview:

Bladder Cancer Therapeutics is an industry that offers therapies and products that treat the bladder. The primary aim of treatment is to prevent or slow the progression of the disease. It also helps to reduce mortality. Several treatment options are available, ranging from chemotherapy to immunotherapy. Immunotherapy is a form of cancer therapy that stimulates the body's immune system to fight cancer. This method has gained traction as an effective treatment for bladder cancer. Intravesical therapy is a form of immunotherapy that uses a drug that is injected into the bladder. This method can be used for stage II or III bladder cancers. Chemotherapy is another common method for treating bladder cancer. Chemotherapy is given by vein, whereas it can be drained into the bladder as well. Radiation therapy for bladder cancer is often combined with chemotherapy.

 

Market Dynamics:

Growing product approvals is anticipated to propel growth of the global bladder cancer therapeutics market over the forecast period. For instance, Merck KGaA and Pfizer declared that the PD-L1 inhibitor Bavencio has gained approval from the US FDA in January 2020. The positive data from the phase III studies have shown better results in patients suffering from metastatic urothelial cancer. Moreover, increasing costs of bladder cancer therapies is estimated to hinder growth of the global bladder cancer therapeutics market over the forecast period.

Impact of COVID-19:

The pandemic was first reported in 2019 and it had significant impact on many countries around the world. The outbreak of the virus directly affected the economy of many countries globally. It also affected the demand and production of various products. The pandemic had a huge impact on the healthcare sector. The healthcare sector was battling with COVID-19 and it was facing several challenges like shortage of medical equipment, skilled professionals and many more. The healthcare sector was more focusses on attending to COVID-19 patients, this led to delaying other treatments. This hampered the growth of the global bladder cancer therapeutics market. As many organizations and pharmaceuticals were focusing on developing vaccines and drugs for COVID-19. However, in the post-pandemic era the market is estimated to witness growth.

Key Takeaways:

The global bladder cancer therapeutics market is anticipated to witness significant growth, exhibiting CAGR of XX% over the forecast period, owing to growing research and developmental activities. For instance, a clinical study was launched by Nanostics Inc., in July 2022, for validating the ClarityDX Bladder, a minimally invasive bladder cancer diagnostic test. The test will be performed using the ClarityDX diagnostic platform.

North America is anticipated to witness significant growth in the global bladder cancer therapeutics market over the forecast period, due growing research and development activities and rising expenditure on healthcare in the region.

Major players operating in the global bladder cancer therapeutics market are Celgene Corporation, AstraZeneca, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Lilly, Sanofi, F. Hoffmann-La Roche Ltd., Pfizer Inc., GSK plc, and Novartis AG.